Parkinson’s Disease in Primary Care: A Practical Canadian Primer
Abstract
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that is increasingly encountered in Canadian primary care. National surveillance data estimate that over 110,000 Canadians are living with Parkinsonism, with incidence rising steadily as the population ages. Approximately 80% of new diagnoses occur after the age of 65 years, making PD highly relevant to geriatric-focused primary care practice. For family physicians, PD represents not only a diagnostic challenge but also a longitudinal care responsibility that intersects with multimorbidity, polypharmacy, fall risk, and caregiver burden.
The diagnosis of PD remains clinical. It requires recognition of Parkinsonism, defined as bradykinesia in combination with rest tremor and/or rigidity, and on an assessment of whether the clinical features support idiopathic PD versus alternative etiologies such as drug-induced, vascular, or atypical Parkinsonism. In primary care, a structured approach that incorporates a focused history, bedside motor examination, and screening for non-motor symptoms can significantly improve diagnostic accuracy.
Management begins with patient education, early initiation of exercise, and symptom-guided pharmacotherapy. Levodopa remains the most effective treatment for motor symptoms and should not be delayed once functional impairment emerges. Primary care clinicians are well positioned to initiate therapy, monitor therapeutic response, and coordinate multidisciplinary care, particularly in regions where access to neurology is limited.
References
Government of Canada. Parkinsonism in Canada, including Parkinson disease [Internet]. 2025 [cited 2026 Mar 31]. Available from: https://health-infobase.canada.ca/datalab/parkinson-blog.html
Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591-1601. doi:10.1002/mds.26424
Frank C, Chiu R, Lee J. Parkinson disease primer, part 1: diagnosis. Can Fam Physician. 2023;69(1):20-24. doi:10.46747/cfp.690120
Grimes D, Fitzpatrick M, Gordon J, Miyasaki J, Fon EA, Schlossmacher M, et al. Canadian guideline for Parkinson disease. CMAJ. 2019;191(36):E989-E1004. doi:10.1503/cmaj.181504
Chaudhuri KR, Healy DG, Schapira AH; National Institute for Clinical Excellence. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 2006;5(3):235-245. doi:10.1016/S1474-4422(06)70373-8
Shin HW, Chung SJ. Drug-induced Parkinsonism. J Clin Neurol. 2012;8(1):15-21. doi:10.3988/jcn.2012.8.1.15
McFarland NR, Hess CW. Recognizing Atypical Parkinsonisms: “Red Flags” and therapeutic approaches. Semin Neurol. 2017;37(2):215-227. doi:10.1055/s-0037-1602422
Udagedara TB, Dhananjalee Alahakoon AM, Goonaratna IK. Vascular Parkinsonism: a review on management updates. Ann Indian Acad Neurol. 2019;22(1):17-20. doi:10.4103/aian.AIAN_194_18
Thenganatt MA, Louis ED. Distinguishing essential tremor from Parkinson’s disease: bedside tests and laboratory evaluations. Expert Rev Neurother. 2012;12(6):687-696. doi:10.1586/ern.12.49
Fasano A, Elia AE, Dallocchio C, Canesi M, Alimonti D, Sorbera C, et al. Predictors of COVID-19 outcome in Parkinson’s disease. Parkinsonism Relat Disord. 2020;78:134-137. doi:10.1016/j.parkreldis.2020.08.012
Dalrymple-Alford JC, MacAskill MR, Nakas CT, Livingston L, Graham C, Crucian GP, et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology. 2010;75(19):1717-1725. doi:10.1212/WNL.0b013e3181fc29c9
Romenets SR, Wolfson C, Galatas C, Pelletier A, Altman R, Wadup L, et al. Validation of the non-motor symptoms questionnaire (NMS-Quest). Parkinsonism Relat Disord. 2012;18(1):54-58. doi:10.1016/j.parkreldis.2011.08.013
Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ. Assessment of autonomic dysfunction in Parkinson’s disease: the SCOPA-AUT. Mov Disord. 2004;19(11):1306-1312. doi:10.1002/mds.20153
PD Med Collaborative Group, Gray R, Ives N, Rick C, Patel S, Gray A, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384(9949):1196-1205. doi:10.1016/S0140-6736(14)60683-8
Frank C, Chiu R, Lee J. Parkinson disease primer, part 2: management of motor and nonmotor symptoms. Can Fam Physician. 2023;69(2):91-96. doi:10.46747/cfp.690291
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Canadian Primary Care Today

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.